“No arrhythmia signal has been seen. There is actually a reduction in both atrial and ventricular arrhythmias,” said Dr. Mann, professor of internal medicine and chief of the division of cardiovascular medicine at Washington University in St. Louis.
The AUGMENT-HF trial was sponsored by LoneStar Heart. Dr. Anker reported having no financial relationship with LoneStar, although he serves as a consultant to half a dozen other health care companies.